UK Approves Foundayo Oral GLP-1 Pill; NHS Decision Pending
The UK has become the first European nation to approve Eli Lilly’s Orforglipron, sold as Foundayo, a once-daily GLP-1 pill for weight management and type 2 diabetes with specific BMI criteria and a multi-dose ramp-up. The MHRA emphasized prescription-only status and ongoing safety reviews, with NHS access still under consideration by NICE and not yet widely available.
